Compellis Pharmaceuticals, Inc.
 

About Compellis

Compellis Pharmaceuticals is an early-stage biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity and related disorders. The company reformulates FDA approved products and identifies proprietary delivery methods to treat broad metabolic disorders and improve quality of life.

 

Mission:
Committed to creating medicines that better the quality of life for patients suffering from health-related conditions, illness or disease; and bringing therapies to those that need them as rapidly as possible.
 
Product Focus:
Innovative Medicines for:
- Obesity
- Diabetes
- Hypertension
 
Contact:
Compellis Pharmaceuticals
141 PowderHouse Blvd. Suite 1
Boston, MA 02144
617-957-9858 (Tel)
617-625-4132 (Fax)
info@compellis.co

 

 

 

Latest Company News

October 27, 2008:

Compellis Pharmaceuticals, Inc. Awarded Second Broad Patent from the U.S. Patent Office for Novel Obesity Therapy

 Drug blocks olfactory sensory perception and may lead to weight loss  (full press release)

January 7, 2008:

Pennington Biomedical Research Institute receives FDA approval to begin Phase I studies of Compellis Pharmaceuticals' novel and patented obesity therapy

Therapy blocks olfactory sensory perception that may lead to a reduction in appetite and cause weight loss

Boston, Mass., January 7, 2008  (full press release)

December 6, 2006:

Compellis Pharmaceuticals Awarded Patent for its Therapeutic Platform for Treating Obesity

Patent covers therapy that blocks olfactory sensory perception which may lead to reduction in appetite and weight loss.

Boston, Mass., December 6, 2006 - (full press release)

© Copyright 2008, Compellis Pharmaceuticals, Inc. All rights reserved.